Brain and Nerves
-
Plain Language Summary: Amyloid-β pathway in Alzheimer’s disease
This Plain Language Summary Publication from Neurodegenerative Disease Management looks at the evidence supporting the role of the amyloid-β (Aβ) pathway, how the pathway is not regulated in Alzheimer’s disease (AD), and highlights the reasons why drugs target the Aβ pathway in the early stages of the disease. Read the full article here. The original […]
-
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets
This plain language summary from Neurodegenerative Disease Management describes the MAGNIFY-MS study, which investigated whether cladribine tablets affect how well the body responds to flu and chickenpox virus vaccines in people with multiple sclerosis.
-
Plain language summary: what symptoms should be measured in clinical studies for early-stage Parkinson’s?
This plain language summary from Future Neurology describes the results of a study into which symptoms are most important to people with Parkinson’s in the earlier stages of their condition, and which symptoms would be appropriate to measure in future clinical studies.
-
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
Learn about the findings from an international committee of 10 MS experts who developed recommendations to answer questions about COVID-19 vaccines in people with MS taking cladribine tablets in this plain language summary.
-
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary
In this plain language summary of publication from Neurodegenerative Disease Management, the researchers look at the results from the CLARITY and CLARITY Extension studies to determine what effect a 2-year course of treatment with cladribine tablets had on disability over 5 years in people with multiple sclerosis.
-
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary
The latest plain language summary of publication from Neurodegenerative Disease Management presents the results from the CLARITY and CLARITY Extension studies.
-
The AT(N) system for describing biological changes in Alzheimer’s disease: a plain language summary
Neurodegenerative Disease Management has published it’s second plain language summary to help people learn more about new techniques to diagnose and treat Alzheimer’s disease. This summary provides an overview of an article discussing a new classification system used to improve diagnosis of Alzheimer’s disease.
-
Plain language summary of the effects of iclepertin (BI 425809) on cognition in patients with schizophrenia
The latest plain language summary in Future Neurology provides an overview of a study looking at the investigational drug iclepertin for the treatment of cognitive symptoms in people with schizophrenia.
-
Once-nightly sodium oxybate (FT218) improved symptoms in people with narcolepsy: a plain language summary of publication
Future Neurology has published it’s first plain language summary of publication. The article summarises the REST-ON study that looked at the investigational treatment sodium oxybate (FT218) for people with narcolepsy symptoms.
-
Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study
This plain language summary of publication, co-authored by a patient, a caregiver and a treating physician, includes the patient perspective and help patients with Duchenne muscular dystrophy and their caregivers understand the results of the Cincinnati study.
-
Family planning in people with multiple sclerosis: a plain language summary
A new plain language summary of publication has been published in Neurodegenerative Disease Management to understand the various concerns people with multiple sclerosis may have about pregnancy and fertility.
-
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary
A new plain language summary has been published to help people with multiple sclerosis understand the side effects of cladribine treatment.